Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy

Ishibashi, Keiichiro; Kumai, Takumi; Ohkuri, Takayuki; Kosaka, Akemi; Nagato, Toshihiro; Hirata, Yui; Ohara, Kenichi; Oikawa, Kensuke; Aoki, Naoko; Akiyama, Naoko; Sado, Masatoshi; Kitada, Masahiro; Harabuchi, Yasuaki; Celis, Esteban; Kobayashi, Hiroya

doi:10.1080/2162402x.2016.1169356

Cited by 32 publications

(37 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, a large body of research has demonstrated that blockade of HLA‐G and ILTs could restore the cytotoxicity of NK cells . For T cells, HLA‐G‐derived peptides HLA‐G 146–154 and HLA‐G 26–40 could effectively induce peptide‐specific CD8 + T cytotoxicity and tumor‐reactive CD4 + T‐cell responses, respectively, rendering the possibility of HLA‐G peptide‐based tumor immunotherapy . Finally, targeting tumor‐specific HLA‐G to develop drug delivery systems has been carried out.…”

Section: Translational Implications Of the Intercellular Transfer Of mentioning

confidence: 99%

“…75 For T cells, HLA-G-derived peptides HLA-G 146-154 and HLA-G [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] could effectively induce peptidespecific CD8 + T cytotoxicity and tumor-reactive CD4 + T-cell responses, respectively, rendering the possibility of HLA-G peptide-based tumor immunotherapy. 76,77 Finally, targeting tumor- specific HLA-G to develop drug delivery systems has been carried out. An HLA-G antibody conjugated to the surface of methotrexate (MTX)loaded nanobubbles (mAb HLA-G /MTX/PLGA NBs) could be specifically transported to the HLA-Gpositive choriocarcinoma cancer cells JEG-3 in vitro and tumor tissues in vivo in a tumor-bearing murine model of BALB/c (nu/nu) nude mice established with JEG-3 cells.…”

Section: Translational Implications Of the Intercellular Transfer Of mentioning

confidence: 99%

See 1 more Smart Citation

Intercellular transfer of HLA‐G: its potential in cancer immunology

Lin

Yan

2019

Clin & Trans Imm

View full text Add to dashboard Cite

Intercellular protein transfer between cancer cells and immune cells is a very common phenomenon that can affect different stages of host antitumor immune responses. HLA‐G, a non‐classical HLA class I antigen, has been observed to be widely expressed in various malignancies, and its immune‐suppressive functions have been well recognised. HLA‐G expression in cancer cells can directly mediate immune tolerance by interacting with inhibitory receptors such as ILT2 and ILT4 expressed on immune cells. Moreover, a network of multiple directional intercellular transfers of HLA‐G among cancer cells and immune cells through trogocytosis, exosomes and tunnelling nanotubes provides malignant cells with an alternative ploy for antigen sharing and induces more complex heterogeneity, to modulate immune responses, ultimately leading to immune evasion, therapy resistance, disease progression and poor clinical outcome. Herein, we discuss the relative aspects of the intercellular transfer of HLA‐G between tumor cells and immune cells and its potential use in tumor immunology research and translational cancer therapy.

show abstract

Section: Translational Implications Of the Intercellular Transfer Of mentioning

confidence: 99%

Section: Translational Implications Of the Intercellular Transfer Of mentioning

confidence: 99%

Intercellular transfer of HLA‐G: its potential in cancer immunology

Lin

Yan

2019

Clin & Trans Imm

View full text Add to dashboard Cite

show abstract

“…Expression levels of HLA-G increase in BC,21 which associates with poor prognosis 22. Following studies on a 14 bp InDel polymorphism in the HLA-G gene, Haghi et al performed genotyping and found that patients with higher BC stages had a higher frequency of allele deletion compared with patients with lower stages, indicating that the 14 bp InDel polymorphism in the HLA-G gene was a risk factor for the development of BC 23.…”

Section: Tumor-related Immune Evasionmentioning

confidence: 99%

Mechanism of immune evasion in breast cancer

Wang¹,

Zhang²,

Song³

et al. 2017

OTT

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignant tumor among women, with high morbidity and mortality. Its onset, development, metastasis, and prognosis vary among individuals due to the interactions between tumors and host immunity. Many diverse mechanisms have been associated with BC, with immune evasion being the most widely studied to date. Tumor cells can escape from the body’s immune response, which targets abnormal components and foreign bodies, using different approaches including modification of surface antigens and modulation of the surrounding environment. In this review, we summarize the mechanisms and factors that impact the immunoediting process and analyze their functions in detail.

show abstract

“…One peptide, HLA-G 146–154 , was observed to effectively induce peptide-specific CTLs and these exhibited cytotoxic activity against HLA-G-expressing HLA-A24-positive renal cell carcinoma cells [109]. Furthermore, a recent study showed that a MHC class II-binding peptide, HLA-G 26–40 , was effective in eliciting a tumor-reactive CD4 + T cell response [110]. It will be interesting in the future to explore the opportunities for modulating HLA-G expression in melanoma tumor cells and other tumors or induce an HLA-G peptide-specific immune response as new innovative cancer immunotherapy.…”

Section: Hla-g In Malignant Melanoma: a Role For Cancer Immune Thementioning

confidence: 99%

The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review

Johansen

Lock‐Andersen

Hviid

2016

Journal of Immunology Research

View full text Add to dashboard Cite

Malignant melanoma, a very common type of cancer, is a rapidly growing cancer of the skin with an increase in incidence among the Caucasian population. The disease is seen through all age groups and is very common in the younger age groups. Several studies have examined the risk factors and pathophysiological mechanisms of malignant melanoma, which have enlightened our understanding of the development of the disease, but we have still to fully understand the complex immunological interactions. The examination of the interaction between the human leucocyte antigen (HLA) system and prognostic outcome has shown interesting results, and a correlation between the down- or upregulation of these antigens and prognosis has been seen through many different types of cancer. In malignant melanoma, HLA class Ia has been seen to influence the effects of pharmaceutical drug treatment as well as the overall prognosis, and the HLA class Ib and regulatory T cells have been correlated with tumor progression. Although there is still no standardized immunological treatment worldwide, the interaction between the human leucocyte antigen (HLA) system and tumor progression seems to be a promising focus in the way of optimizing the treatment of malignant melanoma.

show abstract

Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy

Cited by 32 publications

References 44 publications

Intercellular transfer of HLA‐G: its potential in cancer immunology

Intercellular transfer of HLA‐G: its potential in cancer immunology

Mechanism of immune evasion in breast cancer

The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review

Contact Info

Product

Resources

About